Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1982 2
1983 4
1984 5
1985 3
1986 6
1987 3
1988 1
1989 1
1990 1
1992 1
1993 1
1996 2
1997 3
1999 1
2000 5
2001 1
2002 3
2003 3
2004 5
2005 5
2006 3
2007 1
2008 3
2009 1
2010 4
2011 4
2012 2
2013 5
2014 6
2015 5
2016 1
2017 1
2018 1
2019 2
2020 3
2021 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Black DM, et al. Among authors: santora ac. JAMA. 2006 Dec 27;296(24):2927-38. doi: 10.1001/jama.296.24.2927. JAMA. 2006. PMID: 17190893 Clinical Trial.
History of alendronate.
Cummings SR, Santora AC, Black DM, Russell RGG. Cummings SR, et al. Among authors: santora ac. Bone. 2020 Aug;137:115411. doi: 10.1016/j.bone.2020.115411. Epub 2020 May 11. Bone. 2020. PMID: 32437874
Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study.
Tripto-Shkolnik L, Szalat A, Tsvetov G, Rouach V, Sternberg C, Hoppe A, Burshtein G, Galitzer H, Toledano M, Harari G, Santora AC, Cosman F. Tripto-Shkolnik L, et al. Among authors: santora ac. J Bone Miner Res. 2024 Jul 23;39(6):672-682. doi: 10.1093/jbmr/zjae057. J Bone Miner Res. 2024. PMID: 38578978 Clinical Trial.
Adherence to treatment of osteoporosis: a need for study.
Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY; Group for the Respect of Ethics and Excellence in Science (GREES). Lekkerkerker F, et al. Among authors: santora a. Osteoporos Int. 2007 Oct;18(10):1311-7. doi: 10.1007/s00198-007-0410-4. Epub 2007 Jun 22. Osteoporos Int. 2007. PMID: 17585359 Free article. Review.
A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP 2nd, Rosenberg E, Denker AE. Cosman F, et al. Among authors: santora a. Osteoporos Int. 2016 Jan;27(1):377-86. doi: 10.1007/s00198-015-3392-7. Epub 2015 Nov 10. Osteoporos Int. 2016. PMID: 26556736 Clinical Trial.
A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.
Halse J, Greenspan S, Cosman F, Ellis G, Santora A, Leung A, Heyden N, Samanta S, Doleckyj S, Rosenberg E, Denker AE. Halse J, et al. Among authors: santora a. J Clin Endocrinol Metab. 2014 Nov;99(11):E2207-15. doi: 10.1210/jc.2013-4009. Epub 2014 Aug 28. J Clin Endocrinol Metab. 2014. PMID: 25166719 Free PMC article. Clinical Trial.
96 results